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  Abstract 
    Background and aims.   We have demonstrated recently that transplantation of placental membrane-derived cells reduces 
bleomycin-induced lung ﬁ  brosis in mice, despite a limited presence of transplanted cells in host lungs. Because placenta-
derived cells are known to release factors with potential immunomodulatory and trophic activities, we hypothesized that 
transplanted cells may promote lung tissue repair via paracrine-acting molecules. To test this hypothesis, we examined 
whether administration of conditioned medium (CM) generated from human amniotic mesenchymal tissue cells (AMTC) 
was able to reduce lung ﬁ  brosis in this same animal model.   Methods.   Bleomycin-challenged mice were either treated with 
AMTC-CM or control medium, or were left untreated (Bleo group). After 9 and 14 days, the distribution and severity of 
lung ﬁ  brosis were assessed histologically with a scoring system. Collagen deposition was also evaluated by quantitative 
image analysis.   Results.   At day 14, lung ﬁ  brosis scores in AMTC-CM-treated mice were signiﬁ  cantly lower (  P        0.05) 
compared with mice of the Bleo group, in terms of ﬁ  brosis distribution [1.0 (interquartile range, IQR 0.9) versus 3.0 (IQR 
1.8)], ﬁ  broblast proliferation [0.8 (IQR 0.4) versus 1.6 (IQR 1.0)], collagen deposition [1.4 (IQR 0.5) versus 2.0 (IQR 
1.2)] and alveolar obliteration [2.3 (IQR 0.8) versus 3.2 (IQR 0.5)]. No differences were observed between mice of the 
Bleo group and mice treated with control medium. Quantitative analysis of collagen deposition conﬁ  rmed these ﬁ  ndings. 
Importantly, AMTC-CM treatment signiﬁ  cantly reduced the ﬁ  brosis progression between the two observation time-points. 
  Conclusions.   This pilot study supports the notion that AMTC exert anti-ﬁ  brotic effects through release of yet unknown 
soluble factors.   
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    Introduction 
  Recent ﬁ  ndings indicate compelling beneﬁ  ts of cell-
based treatments in animal models of lung diseases 
associated with inﬂ  ammatory and ﬁ  brotic processes 
(1). For example, transplantation of adult multipotent 
cells [e.g. bone marrow (BM)-derived mesenchymal 
stem cells (MSC) (2,3) and committed alveolar pro-
genitor cells (4,5)], as well as transplantation of cells 
of fetal origin [such as placenta-derived cells (6,7) and 
human umbilical cord Wharton  ’  s jelly  -  derived cells 
(8)], has been shown to reduce lung ﬁ  brosis in animal 
models of bleomycin-induced pulmonary injury. 
  The mechanisms whereby these cell-based treat-
ments are effective in reducing ﬁ  brosis in the lung 
remain poorly deﬁ   ned. Although initial interest 
focused on the level of engraftment of transplanted 
cells in host lungs and their potential for regenerating 
lung tissue by tissue-speciﬁ  c differentiation, the infre-
quency with which either occurrence has been docu-
mented makes it likely that additional mechanisms 
must account for the observed improvements (1). In 
this regard, we have reported previously that trans-
plantation of either allogeneic or xenogeneic placen-
tal membrane-derived cells signiﬁ  cantly reduced the 
severity of bleomycin-induced lung ﬁ  brosis in mice, 
despite a rare persistence of donor cells in the lungs 
of recipient animals (6). In addition, we found that 
human amniotic membrane patches reduced post-
ischemic cardiac scars and liver ﬁ  brosis in rat models 
of coronary artery and bile duct ligation, respectively 
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(9,10). Importantly, we did not observe detectable 
levels of amniotic membrane-derived cells in organs 
treated using these approaches. In other studies, we 
have shown that amniotic membrane-derived cells, 
and in particular cells isolated from the mesenchymal 
region of this membrane, exert immunomodulatory 
actions through the release of soluble factors (11,12). 
In addition, placental membrane-derived cells are 
able to secrete a number of biologically active mol-
ecules with potentially multifaceted activities, such as 
cytokines (13,14), angiogenic factors associated with 
wound healing (15) and growth factors related to cell 
proliferation and differentiation (15  –  17). 
  Based on these ﬁ  ndings, we have put forward the 
hypothesis that the anti-ﬁ  brotic effects observed after 
transplantation of placental cells are mainly related to 
paracrine actions exerted on host tissues by bioactive 
molecules secreted by these cells. An important role 
for soluble factors in stem/progenitor cell-mediated 
reparative effects has been supported by animal exper-
iments using conditioned culture medium (CM) as an 
effective treatment for different tissue injuries. Indeed, 
in a porcine model of myocardial ischemia and reper-
fusion, intravenous and intracoronary injection of CM 
obtained from human MSC cultures reduced infarct 
size and improved cardiac performance (18). Further-
more, systemic infusion of human MSC-CM has been 
shown to reduce apoptosis and stimulate proliferation 
of hepatocytes in a rat model of acute liver injury (19). 
In addition, intramuscular injection of CM derived 
from human endothelial progenitor cells has resulted 
in tissue revascularization and functional recovery in 
a rat model of chronic hindlimb ischemia (20). 
  In this study, we evaluated the effects of admin-
istrating CM generated from cells derived from the 
mesenchymal region of human amniotic membrane 
(amniotic mesenchymal tissue, AMTC) (11) on bleo-
mycin-induced lung ﬁ  brosis, and observed a reduc-
tion of ﬁ  brosis progression similar to that observed 
previously after allogeneic and xenogeneic placental 
membrane-derived cell transplantation. These proof 
of the principle results open the way to consider-
ation of cell-free treatment approaches for ﬁ  brotic 
lung diseases.     
  Methods   
  AMTC isolation 
  Human term placentas (  n         8) were obtained fol-
lowing spontaneous vaginal delivery or Caesarean 
sections, with informed maternal consent according 
to the guidelines of the Institutional Ethics Commit-
tee (CEIOC, Ethics Committee of Catholic Hos-
pital Institutions). After mechanical separation from 
the chorion, the amniotic membrane was washed 
extensively in phosphate-buffered saline (PBS; 
Sigma, St Louis, MO, USA) containing 100 U/mL 
penicillin  and 100   μ  g/mL streptomycin (both 
from EuroClone, Wetherby, UK), and then cut into 
3       3-cm fragments. Cells from the mesenchymal 
region of amniotic membrane were then isolated 
with a well established protocol that was set up at 
Centro di Ricerca E. Menni, Brescia, Italy, which 
is based on separation of the amniotic membrane 
from the chorionic membrane and subsequent enzy-
matic digestion, as described previously (11,21). We 
refer to these cells as AMTC (11,12). After passage 
(P) 2 in culture, these cells display a typical mesen-
chymal stromal phenotype, with the expression of 
markers such as CD90, CD73 and CD105        90% 
and the expression of hematopoietic markers, includ-
ing CD45 and HLA-DR,       2% (21,22). Freshly iso-
lated AMTC display the following phenotype: CD90 
(82      3%), CD73 (66      6%), CD105 (6      4%), CD44 
(47       18%), CD166 (14         7%), CD45 (6        3%) 
and HLA-DR (6         3%) (similar to that previously 
reported by Magatti   et al.  ) (11). Data are expressed 
as the mean of the percentage positive cells        SD  of 
at least 10 independent experiments.     
  AMTC cultures and preparation of CM 
  Freshly isolated AMTC were plated in 24-well plates 
(Corning Inc., Corning, NY, USA) at a density of 
1      10 6   cells/well in serum-free culture medium 
(UltraCulture, Lonza, Basel, Switzerland) supple-
mented with 100 U/mL penicillin and 100   μ  g/mL 
streptomycin. 
  To generate AMTC-CM, cells were cultured for 
5 days at 37  °  C in a humidiﬁ  ed atmosphere of 5% CO  2  . 
Supernatants from each plate were then collected, 
pooled, centrifuged at 700  g  , ﬁ  ltered (0.2  μ  m) to remove 
cellular debris and stored at   –  80  °  C. This procedure 
was performed for cells obtained from eight different 
placentas. Finally, all of the collected supernatants were 
pooled, lyophilized and stored at 4  °  C until use, when 
they were dissolved in sterile water to one-quarter of 
the initial volume. Control, non-conditioned medium 
(non-CM) was generated in the same way as above, 
except that no cells were cultured in the plates.     
  Experimental groups and CM injection 
  Animal experiments were carried out in accordance 
with current Italian and European regulations and 
laws on the use and care of animals for research 
(DL. 116/27 January 1992). All animal procedures 
were performed under general anesthesia (intraperi-
toneal injection of 2 mg/kg xylazine and 100 mg/kg 
ketamine). 
  Seventy 8  –  9-week-old C57BL/6 female mice 
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to be bleomycin-sensitive (23), were instilled intratra-
cheally with 4 U/kg bleomycin in a 50-  μ  L volume, as 
described previously (6). Animals were then divided 
randomly into the following three experimental 
groups: Bleo group, mice that received no additional 
treatments; Bleo         non-CM group, mice receiving 
control non-CM treatment; Bleo        AMTC-CM 
group, mice receiving AMTC-CM treatment. As two 
mice died before they were to be euthanized (one 
belonging to the Bleo         non-CM group and one to 
the Bleo         AMTC-CM group), the three resulting 
groups analyzed at days 9 and 14 were as follows. 
Evaluation of ﬁ  brosis at day 9: Bleo group (  n         11), 
Bleo      non-CM group ( n         11) and Bleo      AMTC-CM 
group (  n         11). Evaluation of ﬁ  brosis at day 14: Bleo 
group (  n         12), Bleo       non-CM group (  n         11) and 
Bleo       AMTC-CM group (  n         12). 
  Fifteen minutes after bleomycin instillation, which 
was the same time-point at which we transplanted 
placental fetal membrane-derived cells in our pre-
vious study (6), 100   μ  L reconstituted medium was 
injected intrapulmonarily, in order to deliver the CM 
as close as possible to the site of damage. In detail, 
the anesthetized mice were placed in the left lat-
eral decubitus and CM was injected percutaneously 
into the right ﬁ  fth intercostal space using a 27-gauge 
needle. The needle was advanced approximately 8 
mm into the thorax and quickly removed after injec-
tion. The quantity of medium injected corresponded 
with the volume of CM generated by 4       10 5   cultured 
cells, a number comparable with the number of 
placental mesenchymal cells that were transplanted 
into each mouse in previous experiments (6).     
  Lung ﬁ  brosis evaluation 
  Animals of each experimental group were euthanized 
at day 9 or day 14 after bleomycin instillation. Whole 
lungs of each mouse were formalin-ﬁ  xed for 48 h 
and embedded in parafﬁ  n. Each block was cut at 
two different coronal section planes (at approxi-
mately 500   μ  m distance from each other), represen-
tative of two regions of the maximum observable 
lung area. Consecutive 4-  μ  m thick sections were cut 
and mounted on Superfrost slides (Thermo Scientiﬁ  c, 
Menzel GmbH   &   Co. KG, Braunshweig, Germany) 
and dried overnight at 37  °  C. For each lung, two 
consecutive sections for each plane were stained 
with hematoxylin  –  eosin (HE) and Masson  –  Goldner 
trichrome (MGT). 
  Histologic grading of ﬁ  brosis was performed by a 
veterinary pathologist, who was blinded to the exper-
imental conditions, using a bright-ﬁ  eld microscope 
and following a semi-quantitative method adapted 
from Hagood   et al.   (24). The ﬁ  brotic process was 
assessed by scoring four parameters: ﬁ  brosis distri-
bution, collagen deposition (both on MGT-stained 
sections), ﬁ  broblast proliferation and alveolar oblit-
eration (both on HE-stained sections). Fibrosis dis-
tribution evaluates semi-quantitatively the amount of 
lung area across the whole section that is affected by 
the ﬁ  brotic process, and is expressed as 1, 2, 3 or 4, 
when 1  –  25%, 26  –  50%, 51  –  75% or 76  –  100% of the 
lung area is ﬁ  brotic, respectively. Severity parame-
ters (ﬁ  broblast proliferation, collagen deposition and 
alveolar obliteration) were scored as 1, 2 or 3 when 
pathologic alterations were graded as mild, mod-
erate or severe, respectively. Speciﬁ  cally,  ﬁ  broblast 
proliferation evaluates the presence of spindle cells, 
morphologically indicative of ﬁ  broblasts.  Collagen 
deposition evaluates the presence of green-stained 
collagen areas, and alveolar obliteration evaluates 
the amount of area characterized by the thickening 
of interalveolar septa that reduces alveolar spaces. 
For each animal, the ﬁ  brosis distribution score and 
the ﬁ   brosis severity parameter mean score (of six 
ﬁ   brosis-representative, randomly chosen, non-
overlapping high power ﬁ  elds for each section) were 
represented by the average of the scores obtained 
from the two examined sections. The overall ﬁ  brosis 
score for each animal was obtained by taking the sum 
of each mean score of the ﬁ  brosis severity parameters 
and multiplying this result by the ﬁ  brosis distribution 
mean score.     
  Collagen deposition image morphometric analysis 
  To evaluate collagen deposition quantitatively, we 
adopted a previously described image analysis-
based system (10). Brieﬂ  y, images of MGT-stained 
specimens were captured with a digital camera 
(Olympus Camedia C-4040 ZOOM) and digitalized 
at 1024         768 pixel, 24-bit/pixel resolution with a 
global magniﬁ  cation of        400. Digital images were 
processed to identify, isolate and measure areas occu-
pied by green-stained collagen deposition as a per-
centage of the total lung parenchyma area included in 
each ﬁ  eld. The mean value of measurements obtained 
from three non-overlapping ﬁ  elds per section show-
ing ﬁ  brotic processes was assigned to each animal.     
  Statistical analysis 
  Data are expressed as median values and the rela-
tive interquartile range (IQR). In the ﬁ  gures,  the 
data are represented by box-plot, where the band 
inside the box represents the median value, the box 
represents the IQR and whiskers show the distribu-
tion of the data. Comparisons between values col-
lected at day 9 with those collected at day 14 for the 
same experimental group was performed by using 
the Mann  –  Whitney test (Table I). Comparisons 156   A. Cargnoni et al.   
In contrast, in samples from mice treated with 
AMTC-CM, the scores for all of these parameters 
remained similar to those observed at day 9 and 
were signiﬁ  cantly lower than those observed in both 
control groups, with the exception of the alveolar 
obliteration parameter, where the difference between 
the samples obtained from AMTC-CM-treated 
animals and the non-CM-treated controls did not 
reach statistical signiﬁ  cance (Figure 1F  –  H). Speciﬁ  -
cally, when compared with the other two groups, 
AMTC-CM-treated  mice showed lower ﬁ  broblast 
proliferation [0.8 (IQR 0.4) versus 1.6 (IQR 1.0) for 
the Bleo group (  P        0.05), and versus 1.5 (IQR 1.2) 
for the Bleo       non-CM group (  P        0.01); Figure 1F], 
collagen deposition [1.4 (IQR 0.5) versus 2.00 (IQR 
1.2) for the Bleo group (  P         0.05), and versus 2.2 
(IQR 1.0) for the Bleo         non-CM group (  P        0.01); 
Figure 1G] and alveolar obliteration [2.3 (IQR 0.8) 
versus 3.2 (IQR 0.5) for the Bleo group (  P        0.05), 
and versus 3.1 (IQR 1.2) for the Bleo        non-CM 
group; Figure 1H]. No differences were observed 
among scores for any of the parameters measured in 
lung samples from mice that were left untreated or 
were treated with non-CM (Figure 1F  –  H). 
  Quantitative image morphometric analysis (10) 
of ﬁ  brotic areas conﬁ  rmed the above ﬁ  ndings and 
showed a signiﬁ  cant reduction in collagen deposi-
tion at day 14 in samples from the mice treated with 
AMTC-CM compared with the two control groups, 
with a median value of 6.6% (IQR 5.5) versus 13.2% 
(IQR 7.5) for the Bleo group (  P         0.05) and 13.2% 
(IQR 9.6) for the Bleo         non-CM group (  P        0.05) 
(Figure 2A, B). 
  Comparison of scores for each lung ﬁ  brosis 
parameter at the two observation time-points revealed 
signiﬁ   cant worsening of all parameters in samples 
from mice from the two control groups, with the 
single exception of alveolar obliteration, which did 
not increase signiﬁ  cantly from day 9 to day 14 in the 
mice that were left untreated. Conversely, samples 
from lungs of mice treated with AMTC-CM showed 
no signiﬁ  cant increase in any of the four measured 
lung ﬁ  brosis parameters (Table I). 
  These results were also conﬁ  rmed with the analysis 
of the overall ﬁ  brosis score, which indicated signiﬁ  cant 
reduction in severity and prevention of progression 
of lung ﬁ  brosis in mice treated with AMTC-CM 14 
days after bleomycin instillation. These mice showed 
a score of 4.9 (IQR 6.6) compared to a score of 
20.8 (IQR 15.4), (  P         0.01) and 16.7 (IQR 19.3) 
(  P        0.05) observed in untreated and non-CM-treated 
control mice, respectively (Figure 3). 
  The experimental design used in our studies 
was based on data collection 9 and 14 days after 
intratracheal bleomycin instillation. The use of these 
time-points avoids the confounding aspects of the 
between more than two groups (in order to compare 
results  obtained at each time-point for the three 
experimental groups) were performed by using the 
Kruskal  –  Wallis non-parametric analysis of variance. 
In cases of statistical signiﬁ  cance, the Mann  –  Whitney 
test using Holm  –  Bonferroni  ’  s correction for multiple 
comparisons was applied to assess the differences 
between experimental groups at the speciﬁ  c time-
points (at day 9 or at day 14). A   P  -value      0.05  was 
considered statistically signiﬁ  cant. Statistical analysis 
was performed with SPSS Advanced Statistics 13.0 
(SPSS Inc., Chicago, IL, USA).       
  Results and discussion 
  The aim of this study was to investigate the poten-
tial beneﬁ  cial effects of AMTC-CM on bleomycin-
induced lung ﬁ   brosis. We analyzed the effects of 
AMTC-CM administration on ﬁ  brosis distribution, 
a parameter that reveals the amount of lung area 
affected by the ﬁ  brotic process across the entire sec-
tion examined. At day 9, about one-third of the lung 
area was affected by the ﬁ  brotic process in all three 
experimental groups, with no differences observed 
among the groups (Figure 1A). At day 14, in mice 
left untreated and those treated with non-CM, the 
ﬁ  brotic process had developed further and occupied 
about two-thirds of the total area examined. The 
scores for ﬁ  brosis distribution in these two groups did 
not differ (Figure 1E). In contrast, samples obtained 
at this time-point from the group of mice treated 
with AMTC-CM showed that only one-third of the 
lung area remained affected by the ﬁ  brotic process, 
which resulted in a ﬁ  brotic score that was signiﬁ  cantly 
reduced compared with the two control groups, with a 
median score of 1.00 (IQR 0.9) versus 3.0 (IQR 1.8) 
for the Bleo group (  P         0.05) and 2.5 (IQR 2.0) for 
the Bleo         non-CM group (  P         0.05) (Figure 1E). 
  To investigate further the potential anti-ﬁ  brotic 
actions of AMTC-CM, each lung area that had 
previously been identiﬁ   ed as ﬁ   brotic was analyzed 
and scored for fibroblast proliferation, collagen 
deposition and alveolar obliteration, the three main 
pathologic hallmarks used to describe the severity of 
bleomycin-induced ﬁ  brotic alterations (24). At day 
9, the median scores for each of the three param-
eters were not signiﬁ  cantly different among the three 
experimental groups (Figure 1B  –  D), with the exception 
of the score for ﬁ  broblast proliferation, which was 
lower in the samples from mice treated with non-CM 
compared with mice left untreated (Figure 1B). This 
difference was no longer evident at day 14 (Figure 1F). 
However, at day 14, samples from mice of the control 
groups showed worsening ﬁ  brosis, with more severe 
ﬁ  broblast proliferation, increased collagen accumu-
lation and alveolar obliteration (Figure 1F  –  H).    Amniotic cell culture medium reduces lung ﬁ  brosis     157
show signiﬁ   cant differences in the ﬁ  brotic  process 
compared with that described at day 14 (A. Cargnoni 
  et al.  , unpublished observations). 
  In addition to the same exhaustive histologic 
assessment of ﬁ   brosis on the whole lung tissue 
early inﬂ  ammatory response and allows scoring of 
the lung ﬁ   brotic process at its intermediate and 
maximum levels, as we and others have demonstrated 
previously (2,3,6,25  –  27). Indeed, studies performed 
21 and 28 days after bleomycin instillation do not 
   
Figure 1.         Representation of ﬁ  brosis distribution and severity parameter scores at days 9 and 14 post-intratracheal bleomycin instillation. 
(A  –  D) Fibrosis distribution (A) and severity (B  –  D) at day 9. (E  –  H) Fibrosis distribution (E) and severity (F  –  H) at day 14. (A, E) Fibrosis 
distribution; (B, F) ﬁ  broblast proliferation; (C, G) collagen deposition; (D, H) alveolar obliteration. The number of mice in each group is 
indicated (  n  ). Brackets represent signiﬁ  cant differences between groups;   ∗    P        0.05;   ∗  ∗    P        0.01.  158   A. Cargnoni et al.   
   
Figure 2.         Digital image morphometric analysis of lung collagen deposition. (A) Microphotographs taken before (left panel) and after (right 
panel) the imaging analysis procedure used to quantitate the collagen staining (black areas) from the image. The identiﬁ  cation number of 
each mouse is indicated on each microphotograph. (B) Median values with IQR of quantitative collagen deposition are represented as 
box-plots for Bleo (dark gray), Bleo       non-CM (light gray) and Bleo        AMTC-CM (white) groups. The number of mice in each group is 
indicated (  n  ). Brackets represent signiﬁ  cant differences between groups;   ∗    P        0.05.     Amniotic cell culture medium reduces lung ﬁ  brosis     159
proof of the principle that AMTC-CM can amelio-
rate the outcome of acute toxic insult of the lung if 
administered soon after induction of the injury.     
  It is noteworthy that, even though AMTC-CM 
was injected into the right lung, a reduction in pulmo-
nary ﬁ  brosis was observed in both the left and right 
lung ﬁ  elds, with no detectable differences between 
the two lungs in each mouse. It is conceivable that 
AMTC-CM injected into the right lung can reach the 
left lung through the exchange of ﬂ  uid that occurs 
between communicating airways during respiratory 
function or, possibly, via the systemic circulation after 
absorption by alveolar capillaries, as we have detected 
donor cells in the left lungs of mice after injection of 
amniotic membrane-derived cells in the right lung 
(Cargnoni et al., unpublished observations). 
  Because virtually no effects on the ﬁ  brotic pro-
cess were observed in mice receiving administration 
of non-CM, we conclude that AMTC-CM con-
tained soluble molecules released by AMTC that 
were responsible for the reduction in severity and 
progression of the ﬁ  brotic reaction. Considering that 
increasing evidence has highlighted recently that 
MSC isolated from various sources produce bioac-
tive molecules, which are potentially able to exert 
several types of paracrine effects (e.g. anti-scarring, 
anti-inﬂ   ammatory, anti-apoptotic) on target cells 
(29), and that injection of CM obtained from MSC 
is an effective experimental treatment for different 
tissue injuries (e.g. 18,19), interesting results will no 
doubt be obtained from comparative studies in the 
same animal model that will investigate whether CM 
generated from cells derived from sources other than 
the amniotic membrane can also reduce lung ﬁ  brosis 
in a manner similar to AMTC-CM. 
  Determination of the nature and characteris-
tics of the paracrine soluble molecules involved in 
AMTC-CM-mediated ﬁ  brosis reduction, as well as 
their mechanism(s) of action and their target cells, 
(without subsampling the lungs) of experimen-
tal animals that we have applied in previous stud-
ies (6), the analysis of our current experiments was 
enhanced by the addition of a quantitative evaluation 
of collagen deposition performed by a digital image 
morphometric analysis (28). Our ﬁ  ndings show that 
the  administration of AMTC-CM prevents the 
progression of bleomycin-induced lung ﬁ  brosis and 
results in a signiﬁ  cant reduction in the parameters 
related to the ﬁ  brotic process at day 14 after intra-
tracheal bleomycin instillation. These results are con-
sistent with the beneﬁ  cial effects of transplanted fetal 
membrane-derived cells that we have observed pre-
viously in the same animal model (6), and provides 
    Figure 3.         Representation of overall ﬁ  brosis score at days 9 and 14 
post-intratracheal bleomycin instillation. Box-plots reporting the 
median and IQR of values obtained from the Bleo (dark gray), 
Bleo      non-CM (light gray) and Bleo      AMTC-CM (white) groups 
are represented for each time-point. The number of mice in each 
group is indicated (  n  ). Brackets represent signiﬁ  cant differences 
between groups and time-points;   ∗    P        0.05;   ∗  ∗    P        0.01.  
    Table I. Comparison of ﬁ  brosis parameters between days 9 and 14 within each experimental group.   
Bleo group Bleo        non-CM  group Bleo      AMTC-CM  group
Day 9 Day 14 Day 9 Day 14 Day 9 Day 14
M IQR M IQR P M IQR M IQR P M IQR M IQR P
Fibrosis 
distribution
1.5 1.0 3.0 1.8        0.05 1.0 0.5 2.5 2.0       0.01 1.0 0.3 1.0 0.9 NS
Fibroblast 
proliferation
0.7 0.4 1.6 1.0       0.01 0.2 0.3 1.5 1.2       0.01 0.7 0.5 0.8 0.4 NS
Collagen 
deposition
1.2 0.3 2.0 1.2       0.05 1.0 0.8 2.2 1.0      0.01 1.0 0.5 1.4 0.5 NS
Alveolar 
obliteration
2.7 0.8 3.2 0.5 NS 2.3 0.8 3.1 1.2       0.05 2.5 1.2 2.3 0.8 NS
      Fibrosis progression was observed in the control groups (Bleo and Bleo       non-CM) from days 9 to 14, but was absent in the AMTC-CM 
treated group.     
  Median (M) with IQR of scores obtained from animals of the same group at each time-point. The statistical differences between time-
points of each group are reported as   P  -values, which were calculated as described in the Methods. NS, not signiﬁ  cant.     160   A. Cargnoni et al.   
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